Cited by 247Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Cholinergic–serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease

Open access

Garcia-Alloza, M., Gil-Bea, F.J., Diez-Ariza, M., Chen, C.P.L.-H., Francis, P.T., Lasheras, B., Ramirez, M.J.·2005·Neuropsychologia

DOI 10.1016/j.neuropsychologia.2004.06.007

Open this paper in CoChat — free account

Abstract

Neuropsychiatric symptoms seen in Alzheimer's disease (AD) are not simply a consequence of neurodegeneration, but probably result from differential neurotransmitter alterations, which some patients are more at risk of than others. Therefore, the hypothesis of this study is that an imbalance between the cholinergic and serotonergic systems is related to cognitive symptoms and psychological syndromes of dementia (BPSD) in patients with AD. Cholinergic and serotonergic functions were assessed in post-mortem frontal and temporal cortex from 22 AD patients who had been prospectively assessed with the Mini-Mental State examination (MMSE) for cognitive impairment and with the Present Behavioral Examination (PBE) for BPSD including aggressive behavior, overactivity, depression and psychosis. Not only cholinergic deficits, but also the cholinacetyltransferase/serotonin ratio significantly correlated with final MMSE score both in frontal and temporal cortex. In addition, decreases in cholinergic function correlated with the aggressive behavior factor, supporting a dual role for the cholinergic system in cognitive and non-cognitive disturbances associated to AD. The serotonergic system showed a significant correlation with overactivity and psychosis. The ratio of serotonin to acetylcholinesterase levels was also correlated with the psychotic factor at least in women. It is concluded that an imbalance between cholinergic-serotonergic systems may be responsible for the cognitive impairment associated to AD. Moreover, the major findings of this study are the relationships between neurochemical markers of both cholinergic and serotonergic systems and non-cognitive behavioral disturbances in patients with dementia.

Integrity signals

Registry

Crossref · 10.1016/j.neuropsychologia.2004.06.007

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Diagnostic and Statistical Manual of Mental Disorders
&NA; (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802020-00022 · Cited by 12,603
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
A rapid radiochemical method for the determination of choline acetyltransferase
Fonnum, F. (1975) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1975.tb11895.x · Cited by 2,358
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 2×
“Reflecting the loss of cholinergic innervation, reductions in AChE and ChAT have been reported in AD brains (Francis et al., 1999; Giacobini, 2003).”
Background
CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia
Roth, M., Tym, E., Mountjoy, C. Q., Huppert, F. A., Hendrie, H., Verma, S., & Goddard, R. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.149.6.698 · Cited by 2,090
The Cholinergic Hypothesis of Age and Alzheimer’s Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development
Terry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159

Show all 52 references

Research works printed but not linked: 1

IPA, 1996, Behavioral and psychological signs and symptoms in demenia (BPSSD): Implications for research and treatment, International Psychogeriatrics, 8, 215

Sorted by citations

Neuropsychiatric symptoms in Alzheimer's disease: what might be associated brain circuits?
Rosenberg, P. B., Nowrangi, M. A., & Lyketsos, C. G. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.05.005 · Cited by 302
Monoaminergic neuropathology in Alzheimer’s disease
Šimić, G., Leko, M. B., Wray, S., Harrington, C. R., Delalle, I., Milošević, N. J., Bažadona, D., Buée, L., de Silva, R., Giovanni, G. D., et al. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.001 · Cited by 297
The serotonergic system and cognitive function
Štrac, D. Š., Pivac, N., & Mück‐Šeler, D. (2016) · Translational Neuroscience · doi:10.1515/tnsci-2016-0007 · Cited by 282
The serotonergic system in ageing and Alzheimer's disease
Rodriguez, J. J., Noristani, H. N., & Verkhratsky, A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.010 · Cited by 274
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns
Chen, Y., Dang, M., & Zhang, Z. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00456-1 · Cited by 238
Synthesis, Biological Evaluation, and Molecular Modeling of Donepezil and N-[(5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine Hybrids as New Multipotent Cholinesterase/Monoamine Oxidase Inhibitors for the Treatment of Alzheimer’s Disease
Bolea, I., Juárez‐Jiménez, J., Rı́os, C. D. L., Chioua, M., Pouplana, R., Luque, F. J., Unzeta, M., Marco, J. L., & Samadi, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200853t · Cited by 220
Psychosis in Alzheimer’s Disease
Murray, P. S., Kumar, S., DeMichele‐Sweet, M. A. A., & Sweet, R. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.020 · Cited by 203
Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease
Lanari, A., Amenta, F., Silvestrelli, G., Tomassoni, D., & Parnetti, L. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.09.016 · Cited by 182
Beyond the Cholinergic Hypothesis: Do Current Drugs Work in Alzheimer's Disease?
Martorana, A., Esposito, Z., & Koch, G. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00175.x · Cited by 174
Ultrasonic Vocalizations Induced by Sex and Amphetamine in M2, M4, M5 Muscarinic and D2 Dopamine Receptor Knockout Mice
Wang, H., Liang, S., Burgdorf, J. S., Wess, J., & Yeomans, J. S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001893 · Cited by 172
Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol
O'Hara, R., Schröder, C. M., Mahadevan, R., Schatzberg, A. F., Lindley, S., Fox, S., Weiner, M., Kraemer, H. C., Noda, A., Lin, X., et al. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001978 · Cited by 171
Graded perturbations of metabolism in multiple regions of human brain in Alzheimer's disease: Snapshot of a pervasive metabolic disorder
Xu, J., Begley, P., Church, S. J., Patassini, S., Hollywood, K. A., Jüllig, M., Curtis, M. A., Waldvogel, H. J., Faull, R. L. M., Unwin, R. D., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.03.001 · Cited by 174
5‐HT radioligands for human brain imaging with PET and SPECT
Paterson, L. M., Kornum, B. R., Nutt, D., Pike, V. W., & Knudsen, G. M. (2011) · Medicinal Research Reviews · doi:10.1002/med.20245 · Cited by 154
Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer’s Disease
Wang, H., & Zhang, H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00391 · Cited by 142
Recent developments on the structure–activity relationship studies of MAO inhibitors and their role in different neurological disorders
Kumar, B., Sheetal, S., Mantha, A. K., & Kumar, V. (2016) · RSC Advances · doi:10.1039/c6ra00302h · Cited by 138
5-HT1A receptors and memory
Meneses, A., & Perez-Garcia, G. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.02.001 · Cited by 134
Principles and management of neuropsychiatric symptoms in Alzheimer’s dementia
Nowrangi, M. A., Lyketsos, C. G., & Rosenberg, P. B. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0096-3 · Cited by 138
Naringenin protects AlCl3/D-galactose induced neurotoxicity in rat model of AD via attenuation of acetylcholinesterase levels and inhibition of oxidative stress
Haider, S., Liaquat, L., Ahmad, S., Batool, Z., Siddiqui, R. A., Tabassum, S., Shahzad, S., Rafiq, S., & Naz, N. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227631 · Cited by 127
Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease
Whiley, L., Chappell, K. E., D’Hondt, E., Lewis, M. R., Jiménez, B., Snowden, S. G., Soininen, H. S., Kłoszewska, I., Mecocci, P., Tsolaki, M., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00741-z · Cited by 126
Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease
Joubert, J., Foka, G. B., Repsold, B. P., Oliver, D. W., Kapp, E., & Malan, S. F. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.041 · Cited by 123
Serotonergic system, cognition, and BPSD in Alzheimer’s disease
Chakraborty, S., Lennon, J. C., Malkaram, S. A., Zeng, Y., Fisher, D. W., & Dong, H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.03.050 · Cited by 127
Cholinergic system function and cognition in mild cognitive impairment
Haense, C., Kalbe, E., Herholz, K., Hohmann, C., Neumaier, B., Krais, R., & Heiss, W. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.08.015 · Cited by 127
Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients
Lorke, D. E., Lü, G., Cho, E. Y. P., & Yew, D. T. W. (2006) · BMC Neuroscience · doi:10.1186/1471-2202-7-36 · Cited by 113
Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type
Pinto, T., Lanctôt, K. L., & Herrmann, N. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.01.003 · Cited by 113
Neurochemical basis for symptomatic treatment of Alzheimer's disease
Francis, P. T., Ramírez, M. J., & Lai, M. K. P. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.02.010 · Cited by 104
Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex
Egashira, N., Iwasaki, K., Ishibashi, A., Hayakawa, K., Okuno, R., Abe, M., Uchida, N., Mishima, K., Takasaki, K., Nishimura, R., et al. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.05.010 · Cited by 103
VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux
Mohler, E. G., Shacham, S., Noiman, S., Lezoualc’h, F., Robert, S. J., Gastineau, M., Rutkowski, J., Marantz, Y., Dumuis, A., Bockaert, J., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.016 · Cited by 98
The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia
Engelborghs, S., Vloeberghs, E., Bastard, N. L., Buggenhout, M. V., Mariën, P., Somers, N., Nagels, G., Pickut, B. A., & Deyn, P. P. D. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2007.10.018 · Cited by 95
Depression and Alzheimer's Disease: Is Stress the Initiating Factor in a Common Neuropathological Cascade?
Aznar, S., & Knudsen, G. M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100390 · Cited by 98
Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current Status
Ramírez, M. J., Lai, M. K. P., Tordera, R. M., & Francis, P. T. (2014) · Drugs · doi:10.1007/s40265-014-0217-5 · Cited by 94
4,6-Diphenylpyrimidine Derivatives as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase for the Treatment of Alzheimer’s Disease
Kumar, B., Dwivedi, A. R., Sarkar, B., Gupta, S. K., Krishnamurthy, S., Mantha, A. K., Parkash, J., & Kumar, V. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00220 · Cited by 92
Dietary and genetic compromise in folate availability reduces acetylcholine, cognitive performance and increases aggression: Critical role of S-adenosyl methionine
Chan, A., Tchantchou, F., Graves, V., Rozen, R., & Shea, T. B. (2008) · The Journal of Nutrition, Health & Aging · doi:10.1007/bf02982630 · Cited by 86
Serotonin: modulator of a drive to withdraw.
Tops, M., Russo, S., Boksem, M. A. S., & Tucker, D. M. (2009) · Brain and Cognition · doi:10.1016/j.bandc.2009.03.009 · Cited by 86
NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease
Huang, Y.-J., Lin, C., Lane, H., & Tsaid, G. E. (2012) · Current Neuropharmacology · doi:10.2174/157015912803217288 · Cited by 87
Sex differences in the effect of acute tryptophan depletion on declarative episodic memory: A pooled analysis of nine studies
Sambeth, A., Blokland, A., Harmer, C. J., Kilkens, T. O. C., Nathan, P. J., Porter, R., Schmitt, J. A. J., Scholtissen, B., Sobczak, S., Young, A. H., et al. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.11.009 · Cited by 85
Behavioral and Psychiatric Symptoms of Dementia and Rate of Decline in Alzheimer’s Disease
Gottesman, R. T., & Stern, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01062 · Cited by 89
Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease
Garcı́a-Alloza, M., Tsang, S. W. Y., Gil-Bea, F. J., Francis, P. T., Lai, M. K. P., Marcos, B., Chen, C., & Ramírez, M. J. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.06.003 · Cited by 77
Aging-associated sensory decline and Alzheimer’s disease
Hong, S., Baek, S.-H., Lai, M. K. P., Arumugam, T. V., & Jo, D.-G. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00776-y · Cited by 76
The serotonin 5-HT6receptor: a viable drug target for treating cognitive deficits in Alzheimer’s disease
Geldenhuys, W. J., & der Schyf, C. J. V. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.51 · Cited by 73
Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer’s disease
Samadi, A., Chioua, M., Bolea, I., Rı́os, C. D. L., Iriepa, I., Moraleda, I., Bastida, Á., Esteban, G., Unzeta, M., Galvez‐Ruano, E., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.05.048 · Cited by 70
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis
d’Angremont, E., Begemann, M. J. H., van Laar, T., & Sommer, I. E. C. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.1835 · Cited by 71
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
Giovanni, G. D., Štrac, D. Š., Solé, M., Unzeta, M., Tipton, K. F., Mück‐Šeler, D., Bolea, I., Corte, L., Perković, M. N., Pivac, N., et al. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00541 · Cited by 76
Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials
Mortby, M. E., Adler, L., Agüera-Ortíz, L., Bateman, D. R., Brodaty, H., Cantillon, M., Geda, Y. E., Ismail, Z., Lanctôt, K. L., Marshall, G. A., et al. (2021) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.06.016 · Cited by 69
Hallucinations in Neurodegenerative Diseases
Burghaus, L., Eggers, C., Timmermann, L., Fink, G. R., & Diederich, N. J. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00247.x · Cited by 68
Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?
Dam, D. V., Vermeiren, Y., Dekker, A. D., Naudé, P. J. W., & Deyn, P. P. D. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160502123607 · Cited by 68
Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias
Barton, C., Ketelle, R., Merrilees, J. J., & Miller, B. L. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0618-1 · Cited by 70
The effects of the 5-HT6 receptor agonist EMD and the 5-HT7 receptor agonist AS19 on memory formation
Meneses, A., Perez-Garcia, G., Liy-Salmerón, G., Flores-Galvez, D., Castillo, C., & Castillo, E. F. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.11.023 · Cited by 64
18 F-Fluorodeoxyglucose Positron Emission Tomography Cortical Metabolic Activity Associated with Distinct Agitation Behaviors in Alzheimer Disease
Weissberger, G. H., Melrose, R. J., Narvaez, T. A., Harwood, D. G., Mandelkern, M. A., & Sultzer, D. L. (2017) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2017.01.017 · Cited by 65
Pharmacological profile of essential oils derived from Lavandula angustifolia and Melissa officinalis with anti-agitation properties: focus on ligand-gated channels
Huang, L., Abuhamdah, S. M. A., Howes, M. R., Dixon, C. L., Elliot, M. S. J., Ballard, C. G., Holmes, C., Burns, A. S., Perry, E. K., Francis, P. T., et al. (2008) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp/60.11.0013 · Cited by 63
Emotion Processing Dysfunction in Alzheimer’s Disease: An Overview of Behavioral Findings, Systems Neural Correlates, and Underlying Neural Biology
Chaudhary, S., Zhornitsky, S., Chao, H. H., van Dyck, C. H., & Li, C. R. (2022) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175221082834 · Cited by 66
Human Choline Transporter Gene Variation Is Associated with Corticolimbic Reactivity and Autonomic-Cholinergic Function
Neumann, S. A., Brown, S. M., Ferrell, R. E., Flory, J. D., Manuck, S. B., & Hariri, A. R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.059 · Cited by 61
Neuropharmacology of the Neuropsychiatric Symptoms of Dementia and Role of Pain: Essential Oil of Bergamot as a Novel Therapeutic Approach
Scuteri, D., Rombolà, L., Morrone, L. A., Bagetta, G., Sakurada, S., Sakurada, T., Tonin, P., & Corasaniti, M. T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133327 · Cited by 60
Psychosis in Alzheimer’s Disease
Ballard, C. G., Kales, H. C., Lyketsos, C. G., Aarsland, D., Creese, B., Mills, R., Williams, H., & Sweet, R. A. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01074-y · Cited by 63
Effects of Dietary Supplementation with N-Acetyl Cysteine, Acetyl-l-Carnitine and S-Adenosyl Methionine on Cognitive Performance and Aggression in Normal Mice and Mice Expressing Human ApoE4
Shea, T. B. (2007) · Neuromolecular medicine · doi:10.1007/s12017-007-8005-y · Cited by 59
Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease
Mück‐Šeler, D., Presečki, P., Mimica, N., Mustapić, M., Pivac, N., Perhoč, A. B., Erjavec, G. N., & Folnegović-Šmalc, V. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.07.004 · Cited by 58
Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice
Laursen, B., Mørk, A., Plath, N., Kristiansen, U., & Bastlund, J. F. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.11.012 · Cited by 58
Transcranial Direct Current Stimulation and Cognition in Neuropsychiatric Disorders: Systematic Review of the Evidence and Future Directions
Ciullo, V., Spalletta, G., Caltagirone, C., Banaj, N., Vecchio, D., Piras, F., & Piras, F. (2020) · The Neuroscientist · doi:10.1177/1073858420936167 · Cited by 61
Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia
Vermeiren, Y., Le Bastard, N., Van Hemelrijck, A., Drinkenburg, W. H., Engelborghs, S., & De Deyn, P. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.06.010 · Cited by 56
The Role of Serotonin Receptors in Alzheimer’s disease
Butzlaff, M., & Ponimaskin, E. G. (2016) · Russian Agency for Digital Standardization · doi:10.20388/omp2016.001.0018 · Cited by 56
Metabolic disorder in Alzheimer’s disease
Poddar, M. K., Banerjee, S., Chakraborty, A., & Dutta, D. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00673-z · Cited by 58
BGC20-761, a novel tryptamine analog, enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT6 receptor-mediated mechanism
Mitchell, E. S., Hoplight, B. J., Lear, S. P., & Neumaier, J. F. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.10.002 · Cited by 54
Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer’s Disease
Kumar, R., Kumar, V., Kumar, B., Thakur, A., & Dwivedi, A. R. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210512005508 · Cited by 55
The neurochemistry of agitation in Alzheimer’s disease: a systematic review
Liu, K. Y., Stringer, A., Reeves, S., & Howard, R. J. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.03.003 · Cited by 56
Neurotransmitter measures in the cerebrospinal fluid of patients with Alzheimer's disease: a review.
Štrac, D. Š., Mück‐Šeler, D., & Pivac, N. (2015) · PubMed · Cited by 51
Pharmacological profile of an essential oil derived from Melissa officinalis with anti-agitation properties: focus on ligand-gated channels
Abuhamdah, S. M. A., Huang, L., Elliott, M. S. J., Howes, M. R., Ballard, C. G., Holmes, C., Burns, A. S., Perry, E. K., Francis, P. T., Lees, G., et al. (2008) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.60.3.0014 · Cited by 52
Benefits of Hormone Therapy Estrogens Depend on Estrogen Type: 17β-Estradiol and Conjugated Equine Estrogens Have Differential Effects on Cognitive, Anxiety-Like, and Depressive-Like Behaviors and Increase Tryptophan Hydroxylase-2 mRNA Levels in Dorsal Raphe Nucleus Subregions
Hiroi, R., Weyrich, G., Koebele, S. V., Mennenga, S., Talboom, J., Hewitt, L. T., Lavery, C. N., Mendoza, P., Jordan, A., & Bimonte-Nelson, H. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00517 · Cited by 50
Citalopram for agitation in Alzheimer's disease: Design and methods
Drye, L. T., Ismail, Z., Porsteinsson, A. P., Rosenberg, P. B., Weintraub, D., Marano, C., Pelton, G., Frangakis, C., Rabins, P. V., Munro, C. A., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.01.007 · Cited by 52
Behavioral and neuropsychiatric disorders in Alzheimer's disease
Cortés, N., Andrade, V., & Maccioni, R. B. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180005 · Cited by 57
Escitalopram for agitation in Alzheimer's disease (S‐CitAD): Methods and design of an investigator‐initiated, randomized, controlled, multicenter clinical trial
Ehrhardt, S., Porsteinsson, A. P., Munro, C. A., Rosenberg, P. B., Pollock, B. G., Devanand, D. P., Mintzer, J. E., Rajji, T. K., Ismail, Z., Schneider, L. S. S., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.4946 · Cited by 49
Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer’s Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?
Jha, S. K., Jha, N. K., Kumar, D., Sharma, R., Shrivastava, A., Ambasta, R. K., & Kumar, P. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160623 · Cited by 48
Use of Yokukansan (TJ‐54) in the treatment of neurological disorders: a review
de Caires, S., & Steenkamp, V. (2010) · Phytotherapy Research · doi:10.1002/ptr.3146 · Cited by 45
Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present)
Wang, N., Qiu, P., Cui, W., Yan, X., Zhang, B., & He, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867326666181203124102 · Cited by 45
Fluoxetine delays the cognitive function decline and synaptic changes in a transgenic mouse model of early Alzheimer's disease
Zhou, C., Chao, F., Zhang, Y., Jiang, L. H., Zhang, L., Fan, J., Wu, Y., Dou, X., & Tang, Y. C. (2018) · The Journal of Comparative Neurology · doi:10.1002/cne.24616 · Cited by 47
Mechanistic complexities of bone loss in Alzheimer’s disease: a review
Frame, G., Bretland, K. A., & Dengler-Crish, C. M. (2020) · Connective Tissue Research · doi:10.1080/03008207.2019.1624734 · Cited by 44
Pharmacological interventions for apathy in Alzheimer's disease
Ruthirakuhan, M. T., Herrmann, N., Abraham, E. H., Chan, S., & Lanctôt, K. L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012197.pub2 · Cited by 113
Behavioral effects and ChE measures after acute and repeated administration of malathion in rats
Assini, F. L., Zanette, K. D., Brocardo, P. S., Pandolfo, P., Rodrigues, A. L. S., & Takahashi, R. N. (2005) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2005.05.007 · Cited by 42
The role of nicotinic cholinergic neurotransmission in delusional thinking
Caton, M., Ochoa, E. L. M., & Barrantes, F. J. (2020) · Schizophrenia · doi:10.1038/s41537-020-0105-9 · Cited by 45
Serotonin modulation of hippocampal functions: From anatomy to neurotherapeutics
Bombardi, C., Grandis, A., Pivac, N., Šagud, M., Lucas, G., Chagraoui, A., Lemaire, V., Deurwaerdère, P. D., & Giovanni, G. D. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.031 · Cited by 42
Serotonin fibre sprouting and increase in serotonin transporter immunoreactivity in the CA1 area of hippocampus in a triple transgenic mouse model of Alzheimer’s disease
Noristani, H. N., Olabarria, M., Verkhratsky, A., & Rodriguez, J. J. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07274.x · Cited by 43
EEG-based neurophysiological indicators of hallucinations in Alzheimer's disease: Comparison with dementia with Lewy bodies
Dauwan, M., Linszen, M. M. J., Lemstra, A. W., Scheltens, P., Stam, C. J., & Sommer, I. E. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.03.013 · Cited by 37
Neuroprotective Effects of Citrus reticulata in Scopolamine-Induced Dementia Oxidative Stress in Rats
El‐Khadragy, M. F., Al-Olayan, E. M., & Moneim, A. E. A. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140618105404 · Cited by 40
Cumulative Effect of COMT and 5-HTTLPR Polymorphisms and Their Interaction With Disease Severity and Comorbidities on the Risk of Psychosis in Alzheimer Disease
Borroni, B., Grassi, M., Agosti, C., Archetti, S., Costanzi, C., Cornali, C., Caltagirone, C., Caimi, L., Luca, M. D., & Padovani, A. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000192491.50802.c3 · Cited by 40
Antidepressant-like effect of diphenyl diselenide on rats exposed to malathion: Involvement of Na+K+ ATPase activity
Acker, C. I., Luchese, C., Prigol, M., & Nogueira, C. W. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.069 · Cited by 39
Genetic Variation in the α7 Nicotinic Acetylcholine Receptor is Associated with Delusional Symptoms in Alzheimer’s Disease
Carson, R., Craig, D., Hart, D. J., Todd, S., McGuinness, B., Johnston, J. A., O’Neill, F. A., Ritchie, C. W., & Passmore, A. P. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8048-8 · Cited by 38
Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease
Smith, G. S., Kramer, E., Ma, Y., Hermann, C. R., DHAWAN, V. M., Chaly, T., & Eidelberg, D. (2009) · Brain · doi:10.1093/brain/awn326 · Cited by 38
Lemon Balm and Lavender herbal essential oils: Old and new ways to treat emotional disorders?
Abuhamdah, S. M. A., & Chazot, P. L. (2008) · Current Anaesthesia and Critical Care · doi:10.1016/j.cacc.2008.05.005 · Cited by 38
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease
Hirao, K., Pontone, G. M., & Smith, G. S. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.11.010 · Cited by 38
Behavioural Phenotyping of APPswe/PS1δE9 Mice: Age-Rrelated Changes and Effect of Long-Term Paroxetine Treatment
Olesen, L. Ø., Bouzinova, E. V., Severino, M., Sivasaravanaparan, M., Hasselstrøm, J. B., Finsen, B. R., & Wiborg, O. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165144 · Cited by 37
Increased hippocampal CA1 density of serotonergic terminals in a triple transgenic mouse model of Alzheimer's disease: an ultrastructural study
Noristani, H. N., Meadows, R. S., Olabarria, M., Verkhratsky, A., & Rodríguez, J. J. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.79 · Cited by 36
Kinetics of serotonin oxidation by heme–Aβ relevant to Alzheimer’s disease
Mukherjee, S., Seal, M., & Dey, S. G. (2014) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-014-1193-7 · Cited by 36
Synergistic inhibition of butyrylcholinesterase by galantamine and citalopram
Walsh, R., Rockwood, K. J., Martin, E. V., & Darvesh, S. (2011) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.08.010 · Cited by 35
Pharmacological Therapy for Apathy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Sepehry, A. A., Sarai, M., & Hsiung, G. R. (2017) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2016.426 · Cited by 37
Dementia-related psychosis and the potential role for pimavanserin
Cummings, J. L., Devanand, D. P., & Stahl, S. M. (2020) · CNS Spectrums · doi:10.1017/s1092852920001765 · Cited by 35
Effect of Selective Cholinergic Denervation on the Serotonergic System: Implications for Learning and Memory
Garcı́a-Alloza, M., Zaldua, N., Diez-Ariza, M., Marcos, B., Lasheras, B., Gil-Bea, F. J., & Ramírez, M. J. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240469.20167.89 · Cited by 36
Limited Effects of aneIF2αS51AAllele on Neurological Impairments in the 5xFAD Mouse Model of Alzheimer’s Disease
Paesler, K., Xie, K., Hettich, M. M., Siwek, M. E., Ryan, D. P., Schröder, S., Papazoglou, A., Broich, K., Müller, R., Trog, A., et al. (2015) · Neural Plasticity · doi:10.1155/2015/825157 · Cited by 36
The neural basis of neuropsychiatric symptoms in Alzheimer’s disease
Zhang, N. K., Zhang, S. K., Zhang, L. I., Tao, H. W., & Zhang, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1487875 · Cited by 39
Increased Levels of Brain Adrenomedullin in the Neuropathology of Alzheimer’s Disease
Ferrero, H., Larráyoz, I. M., Martišová, E., Solas, M., Howlett, D. R., Francis, P. T., Gil-Bea, F. J., Martı́nez, A., & Ramírez, M. J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0700-6 · Cited by 35
Current and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease
Morsy, A., & Trippier, P. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190744 · Cited by 36
Effects of DHA-phospholipids, melatonin and tryptophan supplementation on erythrocyte membrane physico-chemical properties in elderly patients suffering from mild cognitive impairment
Cazzola, R., Rondanelli, M., Faliva, M. A., & Cestaro, B. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.09.004 · Cited by 34
Emerging treatments for the behavioral and psychological symptoms of dementia
Anand, A., Khurana, P., Chawla, J. S., Sharma, N., & Khurana, N. (2017) · CNS Spectrums · doi:10.1017/s1092852917000530 · Cited by 36

Authors: Garcia-Alloza, M., Gil-Bea, F. J., Diez-Ariza, M., Chen, C. P. L.-H., Francis, P. T., Lasheras, B., & Ramirez, M. J.
Affiliations: Universidad de Navarra (ES)
Singapore General Hospital (SG)
King's College London (GB)
ORCID: Gil-Bea, F.J.
Chen, C.P.L.-H.
Francis, P.T.
Venue: Neuropsychologia
Publisher: Elsevier BV
Published: 2005-01
Volume: 43
Issue: 3
Pages: 442-449
ISSN: 0028-3932 (ISSN-L)
DOI: 10.1016/j.neuropsychologia.2004.06.007
OpenAlex: W2113839148
Cited by: 244
References: 52
Citations by year: 2026: 4 · 2025: 12 · 2024: 27 · 2023: 12 · 2022: 8 · 2021: 12 · 2020: 10 · 2019: 11 · 2018: 13 · 2017: 10 · 2016: 16 · 2015: 6 · 2014: 12 · 2013: 11 · 2012: 11
FWCI: 5.22
Type: journal article
Language: en
Open access: green
hdl.handle.net
Licence: other-oa
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Neuropsychologia (publishedVersion)
PubMed (publishedVersion)
Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, other-oa)
Research Portal (King's College London) (submittedVersion)
Funders: Instituto de Salud Carlos III
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, cholinergic system, serotonergic system, acetylcholinesterase, serotonin, aggression, overactivity, psychosis, depression, cognitive impairment, frontal cortex, temporal cortex, postmortem brain
MeSH terms: Acetylcholine, Aged, Aged, 80 and over, Aggression, Alzheimer Disease, Cognition Disorders, Depression, Female, Frontal Lobe, Humans, Male, Mental Status Schedule, Psychiatric Status Rating Scales, Psychotic Disorders, Serotonin, Temporal Lobe, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cholinergic–serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks